Search results
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 13 minutes agoSAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will
HanxBio announces the publication of a research paper in Scientific Reports on preclinical...
FOX 59 Indianapolis· 2 days agoHanxBio today announced that it has published a research article titled "Narazaciclib, a novel...
Why Bio-Path Stock Is Soaring - Bio-Path Hldgs (NASDAQ:BPTH)
Benzinga· 7 days agoBPTH shares are trading higher Thursday after the company announced the completion of its second...
Potential new treatment strategy for aggressive leukemia
Medical Xpress· 7 days agoIn findings published in Nature Cancer, researchers reveal that blocking these oxygen-sensing enzymes can significantly halt acute myeloid leukemia ...
Deverra Therapeutics Granted FDA Fast Track Designation for DVX101
Digital Journal· 15 hours agoDesignation Validates Preliminary Data and Supports Accelerated Drug Development SEATTLE, WA / ACCESSWIRE / April 24, 2024 / Deverra Therapeutics, Inc., a clinical-stage biotechnology company ...
FDA grants breakthrough status for Kura Oncology's AML drug candicate By Investing.com
Investing.com· 3 days agoFood and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to its drug...
Moleculin's acute myeloid leukemia treatment gets EMA's orphan drug designation
Seeking Alpha· 7 days agoMoleculin Biotech's Annamycin receives Orphan Drug Designation from the European Medicines Agency for AML treatment, expanding its potential market reach.
CAR-T Plus Stem-Cell Transplant Promising for CD7+ Blood Cancers
MedPage Today· 1 day agoA strategy of sequential CD7 chimeric antigen receptor (CAR) T-cell therapy and haploidentical...
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute ...
NBC 17 Raleigh· 7 days ago– Next-generation non-cardiotoxic anthracycline Annamycin with notable signs of clinical efficacy in AML in combination with Cytarabine achieves preliminary CRc rate of 60% in 2nd line AML subjects ...
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
Zacks via Yahoo Finance· 6 days agoBio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its...